Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tempest Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Tempest Therapeutics, Inc.

TPST

Tempest Therapeutics, Inc.

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. is a clinical-stage biotech company developing targeted and immune-mediated cancer therapies. Its pipeline includes first-in-class oral small molecules like amezalpat for hepatocellular carcinoma and TPST-1495 targeting prostaglandin receptors. The company focuses on innovative oncology treatments, leveraging scientific research, strategic collaborations, and patent protection to address unmet medical needs in cancer markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tempest Therapeutics, Inc.

1
1
Tempest Therapeutics, Inc. Tempest Therapeutics Reports $27.7 Million Net Loss and Strategic Acquisition in Latest 10-Q Filing

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Tempest Therapeutics, Inc. Tempest Therapeutics Shifts Focus to CAR-T and Small Molecule Programs After Strategic Acquisition

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Tempest Therapeutics, Inc. Tempest Therapeutics Reports $3.5 Million Net Loss, Focuses on Strategic Alternatives

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tempest Therapeutics, Inc. Tempest Therapeutics Reports $7.87 Million Net Loss in Q2 2025, Initiates Cost-Reduction Measures

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tempest Therapeutics, Inc. Tempest Therapeutics Reports $10.9 Million Net Loss in Q1 2025, Announces Workforce Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tempest Therapeutics, Inc. Tempest Therapeutics Reports $41.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Tempest Therapeutics, Inc. Tempest Therapeutics Reports Financial Results, Expands Leadership Team, and Advances Clinical Programs

Via official filing (AI summary) | over 1 year ago | 0 comments